Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Lung Cancer

Journal Scan / Research · July 18, 2022

ctDNA Kinetics Predict Progression-Free and Overall Survival in EGFR-TKI–Treated Patients With EGFR-Mutant NSCLC

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)
Clin. Cancer Res 2022 Jun 17;[EPub Ahead of Print], PC Mack, J Miao, MW Redman, J Moon, SB Goldberg, RS Herbst, MA Melnick, Z Walther, FR Hirsch, K Politi, K Kelly, DR Gandara

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading